Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first-line treatment for Chinese population with unresectable hepatocellular carcinoma in Taiwan

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: SAP-057
  • By: TSENG, Chien-Yu (National Yang Ming Chiao Tung University, Taiwan China)
  • Co-author(s): Ms Chien-Yu Tseng, Pharmacy (National Yang Ming Chiao Tung University, Taipei, Taiwan China)
    Dr. Ming-Neng Shiu, Pharmacy (National Yang Ming Chiao Tung University, Taipei, Taiwan China)
  • Abstract:

    Introduction: The IMbrave150 trial showed that the combined treatment of atezolizumab and bevacizumab (A+B) significantly prolonged the overall survival and progression-free survival in unresectable hepatocellular carcinoma (HCC) patients. Moreover, the A+B treatment had higher efficacy in the Chinese subpopulation when compared to the overall..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses